Key result
Sacubitril/valsartan treatment increased peak oxygen uptake by 14.11% (P<0.05 vs control), and baseline troponin-I levels independently predicted this improvement (beta=0.35, P=0.048).
Why the study?
Does sacubitril/valsartan improve peak oxygen uptake in symptomatic patients with chronic HFrEF, and is this response predicted by baseline troponin-I levels?
Population
48 symptomatic patients with chronic HFrEF (LVEF ≤35%) and NYHA class II/III
Comparison
Sacubitril/valsartan 105 ± 30 mg twice daily for… vs No sacubitril/valsartan
Design
Cohort
Follow-up
6 months
Authors
Loading...
May identify troponin-I as predictor of VO2 response to sacubitril/valsartan in HFrEF; leaves open confirmation in randomized trials.
Cohort (n=48)
Does sacubitril/valsartan improve peak oxygen uptake in symptomatic patients with chronic HFrEF, and is this response predicted by baseline troponin-I levels?
p-value: p=<0.05
Baseline troponin-I levels may serve as an independent predictive biomarker for improved exercise capacity following sacubitril/valsartan treatment in patients with HFrEF.
Nakou et al. (2018) conducted a cohort in chronic heart failure with reduced ejection fraction (HFrEF) (n=48). sacubitril/valsartan vs. no sacubitril/valsartan was evaluated on increase in peak oxygen uptake (ΔVO2 max) (p=<0.05). Sacubitril/valsartan treatment increased peak oxygen uptake by 14.11% (P<0.05 vs control), and baseline troponin-I levels independently predicted this improvement (beta=0.35, P=0.048).
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: